m+Medelevator.RU
← Поиск публикаций
Proceedings of the National Academy of Sciences of the United States of America · 2022

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Manry Jérémy, Bastard Paul, Gervais Adrian, Le Voyer Tom, Rosain Jérémie, Philippot Quentin, Michailidis Eleftherios, Hoffmann Hans-Heinrich, Eto Shohei, Garcia-Prat Marina, Bizien Lucy, Parra-Martínez Alba, Yang Rui, Haljasmägi Liis, Migaud Mélanie, Särekannu Karita, Maslovskaja Julia, de Prost Nicolas, Tandjaoui-Lambiotte Yacine, Luyt Charles-Edouard, Amador-Borrero Blanca, Gaudet Alexandre, Poissy Julien, Morel Pascal, Richard Pascale, Cognasse Fabrice, Troya Jesús, Trouillet-Assant Sophie, Belot Alexandre, Saker Kahina, Garçon Pierre, Rivière Jacques G, Lagier Jean-Christophe, Gentile Stéphanie, Rosen Lindsey B, Shaw Elana, Morio Tomohiro, Tanaka Junko, Dalmau David, Tharaux Pierre-Louis, Sene Damien, Stepanian Alain, Mégarbane Bruno, Triantafyllia Vasiliki, Fekkar Arnaud, Heath James R, Franco José Luis, Anaya Juan-Manuel, Solé-Violán Jordi, Imberti Luisa, Biondi Andrea, Bonfanti Paolo, Castagnoli Riccardo, Delmonte Ottavia M, Zhang Yu, Snow Andrew L, Holland Steven M, Biggs Catherine M, Moncada-Vélez Marcela, Arias Andrés Augusto, Lorenzo Lazaro, Boucherit Soraya, Anglicheau Dany, Planas Anna M, Haerynck Filomeen, Duvlis Sotirija, Ozcelik Tayfun, Keles Sevgi, Bousfiha Ahmed A, El Bakkouri Jalila, Ramirez-Santana Carolina, Paul Stéphane, Pan-Hammarström Qiang, Hammarström Lennart, Dupont Annabelle, Kurolap Alina, Metz Christine N, Aiuti Alessandro, Casari Giorgio, Lampasona Vito, Ciceri Fabio, Barreiros Lucila A, Dominguez-Garrido Elena, Vidigal Mateus, Zatz Mayana, van de Beek Diederik, Sahanic Sabina, Tancevski Ivan, Stepanovskyy Yurii, Boyarchuk Oksana, Nukui Yoko, Tsumura Miyuki, Vidaur Loreto, Tangye Stuart G, Burrel Sonia, Duffy Darragh, Quintana-Murci Lluis, Klocperk Adam, Kann Nelli Y, Shcherbina Anna, Lau Yu-Lung, Leung Daniel, Coulongeat Matthieu, Marlet Julien, Koning Rutger, Reyes Luis Felipe, Chauvineau-Grenier Angélique, Venet Fabienne, Monneret Guillaume, Nussenzweig Michel C, Arrestier Romain, Boudhabhay Idris, Baris-Feldman Hagit, Hagin David, Wauters Joost, Meyts Isabelle, Dyer Adam H, Kennelly Sean P, Bourke Nollaig M, Halwani Rabih, Sharif-Askari Fatemeh Saheb, Dorgham Karim, Sallette Jérôme, Sedkaoui Souad Mehlal, AlKhater Suzan, Rigo-Bonnin Raúl, Morandeira Francisco, Roussel Lucie, Vinh Donald C, Erikstrup Christian, Condino-Neto Antonio, Prando Carolina, Bondarenko Anastasiia, Spaan András N, Gilardin Laurent, Fellay Jacques, Lyonnet Stanislas, Bilguvar Kaya, Lifton Richard P, Mane Shrikant, HGID Lab, COVID Clinicians, COVID-STORM Clinicians, NIAID Immune Response to COVID Group, NH-COVAIR Study Group, Danish CHGE, Danish Blood Donor Study, St. James's Hospital, SARS CoV2 Interest Group, French COVID Cohort Study Group, Imagine COVID-Group, Milieu Intérieur Consortium, CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank Investigators, COVID Human Genetic Effort, CP-COVID-19 Group, CONSTANCES cohort, 3C-Dijon Study, Cerba Health-Care, Etablissement Français du Sang Study group, Anderson Mark S, Boisson Bertrand, Béziat Vivien, Zhang Shen-Ying, Andreakos Evangelos, Hermine Olivier, Pujol Aurora, Peterson Pärt, Mogensen Trine H, Rowen Lee, Mond James, Debette Stéphanie, de Lamballerie Xavier, Burdet Charles, Bouadma Lila, Zins Marie, Soler-Palacin Pere, Colobran Roger, Gorochov Guy, Solanich Xavier, Susen Sophie, Martinez-Picado Javier, Raoult Didier, Vasse Marc, Gregersen Peter K, Piemonti Lorenzo, Rodríguez-Gallego Carlos, Notarangelo Luigi D, Su Helen C, Kisand Kai, Okada Satoshi, Puel Anne, Jouanguy Emmanuelle, Rice Charles M, Tiberghien Pierre, Zhang Qian, Casanova Jean-Laurent, Abel Laurent, Cobat Aurélie

Аннотация

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты